Image_2_Natural Vascular Scaffolding Treatment Promotes Outward Remodeling During Arteriovenous Fistula Development in Rats.tiff by Yan-Ting Shiu (9157814)

“…Natural Vascular Scaffolding (NVS) Therapy is a new technology that interlinks collagen and elastin via photoactivation of a locally delivered small molecule (4-amino-1,8-naphtalamide). …”

Data_Sheet_1_Asthma prevalence based on the Baidu index and China's Health Statistical Yearbook from 2011 to 2020 in China.xlsx by Yahui Li (315104)

“…Although China has made early efforts in asthma epidemiology and prevention, there is still a lack of unified and comprehensive epidemiological research within the country. …”

Image_3_Natural Vascular Scaffolding Treatment Promotes Outward Remodeling During Arteriovenous Fistula Development in Rats.tiff by Yan-Ting Shiu (9157814)

“…Natural Vascular Scaffolding (NVS) Therapy is a new technology that interlinks collagen and elastin via photoactivation of a locally delivered small molecule (4-amino-1,8-naphtalamide). …”

DataSheet_6_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_7_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_1_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_10_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_5_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_2_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_2_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_8_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_1_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_3_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_3_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_9_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_6_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

DataSheet_4_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.pdf by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_5_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Table_4_Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.xlsx by Cristina Calviño (17004837)

“…Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I^KO/TCR^KO CAR-T cells that would be compatible with clinical applications. …”

Analyses of Lateral Gene Transfer Events in Bacteroidetes Lineages Reveal Its Contribution to Niche Specialization by Jian Xu (31545)

“…Significant increases (enrichment) relative to each whole genome are shown by an upward-pointing arrowhead, and decreases (depletion) by a downward-pointing arrowhead, whereas the corresponding probability, determined by a binomial test, is denoted by asterisks: a single asterisk (*) indicates <i>p</i> < 0.05; double asterisks (**) indicate <i>p</i> < 0.01; and triple asterisks (***) indicate <i>p</i> < 0.001.…”